Search results
Results from the WOW.Com Content Network
The Billion-Dollar Molecule is a book [1] by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry.
Vols. for Nov.-Dec. 1989-1996 generally monthly with some issues bimonthly, but does not follow a particular pattern Issues for Aug. 1988-Feb. 1996 called v. 1, no. 4-v. 9, no. 2 "Prepared for members of the U.S. Department of Agriculture's Committee on Biotechnology in Agriculture by USDA's Office of Agricultural Biotechnology."
Our Posthuman Future: Consequences of the Biotechnology Revolution is a 2002 book by Francis Fukuyama. In it, he discusses the potential threat to liberal democracy that use of new and emerging biotechnologies for transhumanist ends poses.
The Trends series was established in 1976 with Trends in Biochemical Sciences, rapidly followed by Trends in Neurosciences, Trends in Pharmacological Sciences, and Immunology Today. Immunology Today, Parasitology Today, and Molecular Medicine Today changed their names to Trends in... in 2001. Drug Discovery Today was spun off as an independent ...
Nanotechnology The IBHF reviews the development of nanotechnology policy in the United States and Europe, with special focus on the emerging nanotechnology ethical, legal, and social issues (NELSI). Human cloning [5] “Somatic cell nuclear transfer” technology can be used to bring about the birth of replica offspring, and to create embryos ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The book received positive reviews and became Waldby's most cited work. Writing a positive review, Steve Chasin called the book "a valuable contribution to understanding the landscape of today's rapidly developing biotechnology industry." [11] Ruth McManus called the book "revelatory". [16]
Mary Ann Liebert, Inc. is a privately held independent publishing company founded by its president, Mary Ann Liebert, in 1980. [2] [3] The company publishes peer-reviewed academic journals, books, and trade magazines in the areas of biotechnology, biomedical sciences, medical research, and life sciences; clinical medicine, surgery, and nursing; technology and engineering; environmental science ...